- Home
- BIIB vs DOW Comparison
BIIB vs DOW Comparison
Compare BIIB & DOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- DOW
- Stock Information
- Founded
- BIIB 1978
- DOW 1897
- Country
- BIIB United States
- DOW United States
- Employees
- BIIB N/A
- DOW N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- DOW Major Chemicals
- Sector
- BIIB Health Care
- DOW Industrials
- Exchange
- BIIB Nasdaq
- DOW Nasdaq
- Market Cap
- BIIB 18.8B
- DOW 21.6B
- IPO Year
- BIIB 1991
- DOW N/A
- Fundamental
- Price
- BIIB $134.15
- DOW $29.38
- Analyst Decision
- BIIB Buy
- DOW Hold
- Analyst Count
- BIIB 26
- DOW 15
- Target Price
- BIIB $194.95
- DOW $38.80
- AVG Volume (30 Days)
- BIIB 1.7M
- DOW 8.4M
- Earning Date
- BIIB 07-31-2025
- DOW 07-24-2025
- Dividend Yield
- BIIB N/A
- DOW 9.51%
- EPS Growth
- BIIB 26.39
- DOW N/A
- EPS
- BIIB 10.12
- DOW 0.40
- Revenue
- BIIB $9,816,400,000.00
- DOW $42,630,000,000.00
- Revenue This Year
- BIIB N/A
- DOW N/A
- Revenue Next Year
- BIIB N/A
- DOW $2.78
- P/E Ratio
- BIIB $13.31
- DOW $73.83
- Revenue Growth
- BIIB 1.59
- DOW N/A
- 52 Week Low
- BIIB $110.04
- DOW $25.06
- 52 Week High
- BIIB $238.00
- DOW $57.22
- Technical
- Relative Strength Index (RSI)
- BIIB 62.26
- DOW 52.00
- Support Level
- BIIB $129.61
- DOW $26.49
- Resistance Level
- BIIB $134.74
- DOW $30.29
- Average True Range (ATR)
- BIIB 3.10
- DOW 0.76
- MACD
- BIIB 0.60
- DOW 0.11
- Stochastic Oscillator
- BIIB 86.90
- DOW 76.13
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About DOW Dow Inc.
Dow Chemical is a diversified global chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets.